Table 1 Baseline characteristics of the overall cohort according to annualized hospital volume of VA-ECMO procedures
From: Procedural volume and outcomes in patients undergoing VA-ECMO support
Baseline characteristics | P value | ||||
|---|---|---|---|---|---|
Overall (n = 10,207) | ≤ 50 procedures/Yr (n = 5421) | > 50–100 procedures/Yr (n = 2799) | > 100 procedures/Yr (n = 1987) | ||
Demographics,n(%) | |||||
Mean age, Yr | 61 ± 17 | 62 ± 19 | 61 ± 14 | 61 ± 14 | < 0.001 |
Male gender | 7272 (71.2) | 3879 (71.5) | 1998 (71.4) | 1395 (70.2) | 0.515 |
CPR | 4429 (43.4) | 2637 (48.6) | 1104 (39.4) | 668 (34.6) | < 0.001 |
Baseline comorbidities,n(%) | |||||
AF | 4031 (39.5) | 2849 (36.2) | 1171 (41.8) | 893 (44.9) | < 0.001 |
CAD | 6659 (65.2) | 3713 (68.4) | 1741 (62.2) | 1205 (60.6) | < 0.001 |
CHF | 6803 (66.7) | 3570 (65.8) | 1789 (63.9) | 1444 (72.7) | < 0.001 |
CKD | 2441 (23.9) | 1382 (25.4) | 655 (23.4) | 404 (20.3) | < 0.001 |
COLD | 514 (5.0) | 331 (6.1) | 136 (4.9) | 47 (2.4) | < 0.001 |
PH | 1783 (17.5) | 761 (14.0) | 541 (19.3) | 481 (24.2) | < 0.001 |
HTN | 4821 (47.2) | 2542 (46.8) | 1373 (49.1) | 906 (45.6) | 0.047 |
HLD | 2531 (24.8) | 1351 (24.9) | 698 (24.9) | 482 (24.3) | 0.825 |
Diabetes | 2571 (25.2) | 1383 (25.5) | 669 (23.9) | 519 (26.1) | 0.159 |
Cancer | 278 (2.7) | 169 (3.1) | 79 (2.8) | 30 (1.5) | 0.001 |
Liver disease | 507 (5.0) | 238 (4.3) | 147 (5.3) | 122 (6.1) | 0.006 |
Mean VA-ECMO duration in h (mdn) | 116 (72) | 98 (72) | 128 (120) | 150 (120) | 0.001 |
Indication category for VA-ECMO support,n(%) | |||||
HTX | 179 (1.8) | 22 (0.4) | 75 (2.7) | 82 (4.1) | < 0.001 |
ACS | 6202 (60.8) | 3528 (65.0) | 1583 (56.6) | 1091 (54.9) | < 0.001 |
AHF | 3826 (37.5) | 1871 (34.5) | 1141 (40.8) | 814 (41.0) | < 0.001 |